368 related articles for article (PubMed ID: 29101636)
21. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.
Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z
J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096
[TBL] [Abstract][Full Text] [Related]
22. In vivo MR/optical imaging for gastrin releasing peptide receptor of prostate cancer tumor using Gd-TTDA-NP-BN-Cy5.5.
Lin YH; Dayananda K; Chen CY; Liu GC; Luo TY; Hsu HS; Wang YM
Bioorg Med Chem; 2011 Feb; 19(3):1085-96. PubMed ID: 20493715
[TBL] [Abstract][Full Text] [Related]
23. Folic acid-targeted iron oxide nanoparticles as contrast agents for magnetic resonance imaging of human ovarian cancer.
Zhang H; Li J; Hu Y; Shen M; Shi X; Zhang G
J Ovarian Res; 2016 Mar; 9():19. PubMed ID: 27025582
[TBL] [Abstract][Full Text] [Related]
24. Specific targeting of breast tumor by octreotide-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 3.0-Tesla magnetic resonance scanner.
Li X; Du X; Huo T; Liu X; Zhang S; Yuan F
Acta Radiol; 2009 Jul; 50(6):583-94. PubMed ID: 19449236
[TBL] [Abstract][Full Text] [Related]
25. Imaging tumor-induced sentinel lymph node lymphangiogenesis with LyP-1 peptide.
Zhang F; Niu G; Lin X; Jacobson O; Ma Y; Eden HS; He Y; Lu G; Chen X
Amino Acids; 2012 Jun; 42(6):2343-51. PubMed ID: 21769497
[TBL] [Abstract][Full Text] [Related]
26. Association between MRI Features and Standardized Uptake Value of 18F-FDG PET/CT in Triple-Negative Breast Cancer.
Choi BB; Lee JS; Kim KH
Oncol Res Treat; 2018; 41(11):706-711. PubMed ID: 30321870
[TBL] [Abstract][Full Text] [Related]
27. Folic acid-conjugated superparamagnetic iron oxide nanoparticles for tumor-targeting MR imaging.
Li L; Gao F; Jiang W; Wu X; Cai Y; Tang J; Gao X; Gao F
Drug Deliv; 2016 Jun; 23(5):1726-33. PubMed ID: 25715808
[TBL] [Abstract][Full Text] [Related]
28. Biodistribution Analysis of NIR-Labeled Nanogels Using in Vivo FMT Imaging in Triple Negative Human Mammary Carcinoma Models.
Gordon MR; Zhuang J; Ventura J; Li L; Raghupathi K; Thayumanavan S
Mol Pharm; 2018 Mar; 15(3):1180-1191. PubMed ID: 29378144
[TBL] [Abstract][Full Text] [Related]
29. Theranostics of Triple-Negative Breast Cancer Based on Conjugated Polymer Nanoparticles.
Jin G; He R; Liu Q; Dong Y; Lin M; Li W; Xu F
ACS Appl Mater Interfaces; 2018 Apr; 10(13):10634-10646. PubMed ID: 29323875
[TBL] [Abstract][Full Text] [Related]
30. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI.
Chen TJ; Cheng TH; Chen CY; Hsu SC; Cheng TL; Liu GC; Wang YM
J Biol Inorg Chem; 2009 Feb; 14(2):253-60. PubMed ID: 18975017
[TBL] [Abstract][Full Text] [Related]
31. Fluorescent magnetic nanoparticles with specific targeting functions for combinded targeting, optical imaging and magnetic resonance imaging.
Chen YC; Chang WH; Wang SJ; Hsieh WY
J Biomater Sci Polym Ed; 2012; 23(15):1903-22. PubMed ID: 22024467
[TBL] [Abstract][Full Text] [Related]
32. Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions.
Uchida M; Kosuge H; Terashima M; Willits DA; Liepold LO; Young MJ; McConnell MV; Douglas T
ACS Nano; 2011 Apr; 5(4):2493-502. PubMed ID: 21391720
[TBL] [Abstract][Full Text] [Related]
33. DCE- and DW-MRI as early imaging biomarkers of treatment response in a preclinical model of triple negative breast cancer.
Barnes SL; Sorace AG; Whisenant JG; McIntyre JO; Kang H; Yankeelov TE
NMR Biomed; 2017 Nov; 30(11):. PubMed ID: 28915312
[TBL] [Abstract][Full Text] [Related]
34. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
35. Targeted treatment of triple-negative-breast cancer through pH-triggered tumour associated macrophages using smart theranostic nanoformulations.
Scialla S; Hanafy MS; Wang JL; Genicio N; Costa Da Silva M; Costa M; Oliveira-Pinto S; Baltazar F; Gallo J; Cui Z; Bañobre-López M
Int J Pharm; 2023 Feb; 632():122575. PubMed ID: 36603672
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and Evaluation of Radioiodine-Labeled pH (Low) Insertion Peptide Variant 7-Like Peptide as a Noninvasive Tumor Microenvironment Imaging Agent in a Mouse MDA-MB-231 Triple-Negative Breast Cancer Model.
Wu F; Chen Y; Li D; Wang Z; Yu M
Mol Imaging Biol; 2022 Aug; 24(4):570-579. PubMed ID: 35006491
[TBL] [Abstract][Full Text] [Related]
37. Receptor-targeted nanoparticles for in vivo imaging of breast cancer.
Yang L; Peng XH; Wang YA; Wang X; Cao Z; Ni C; Karna P; Zhang X; Wood WC; Gao X; Nie S; Mao H
Clin Cancer Res; 2009 Jul; 15(14):4722-32. PubMed ID: 19584158
[TBL] [Abstract][Full Text] [Related]
38. Morphological and Semiquantitative Kinetic Analysis on Dynamic Contrast Enhanced MRI in Triple Negative Breast Cancer Patients.
Gigli S; Amabile MI; David E; De Luca A; Grippo C; Manganaro L; Monti M; Ballesio L
Acad Radiol; 2019 May; 26(5):620-625. PubMed ID: 30145205
[TBL] [Abstract][Full Text] [Related]
39. Triple-negative breast cancer on contrast-enhanced MRI and synthetic MRI: A comparison with non-triple-negative breast carcinoma.
Matsuda M; Tsuda T; Ebihara R; Toshimori W; Okada K; Takeda S; Okumura A; Shiraishi Y; Suekuni H; Kamei Y; Kurata M; Kitazawa R; Mochizuki T; Kido T
Eur J Radiol; 2021 Sep; 142():109838. PubMed ID: 34217136
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
